Viva Biotech

Viva Biotech (01873.HK), established in 2008, provides global innovative drug research and development enterprises with one-stop comprehensive services ranging from early structure-based drug discovery to commercial drug delivery. Leveraging our leading advantages in structure-based drug discovery (SBDD) technology, we offer CRO services at the new drug research stage to global partners, featuring advanced technology platforms such as X-ray protein crystallography, Cryogenic Electron Microscopy (Cryo-EM), Affinity Selection Mass Spectrometry (ASMS), Surface Plasmon Resonance (SPR), Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS), computer-aided drug design, and an expert team. Through our subsidiary Langhua Pharma, we provide a one-stop CMC/CDMO solution from preclinical development to commercial production. Meanwhile, we focus on discovering and investing in high-potential biopharmaceutical startups, utilizing a unique business model of exchanging technical services for equity (EFS) to address unmet clinical needs.